AIDS Therapies
Vical To Receive $3 Million Milestone Payment
Published in AIDS Weekly, December 10th, 2001
Vical, Inc., (VICL) has received a $3 million payment from Merck & Co., Inc., (MRK) which has begun human testing of a prime-boost vaccine regimen that employs Vical's patented naked DNA nonviral gene delivery technology to combat human immunodeficiency virus (HIV). Under terms of a 1997 licensing agreement, the payment extends the term of Merck's exclusive worldwide rights to use Vical's naked DNA technology to develop and market therapeutic vaccines against both HIV and the hepatitis B virus (HBV).
"We are delighted that Merck's HIV vaccine program has advanced and that Vical's naked DNA technology remains a key component in Merck's latest efforts," said Vical...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2001-12-10)
More Articles from AIDS Weekly
- AIDS and HIV Vaccine
Monoclonal Antibodies Display Mysterious Synergy - AIDS and HIV Vertical Transmission
Maternal Antiretroviral Resistance Does Not Raise Risk - HIV Therapies
New Finding May Help Physicians Prevent HIV Drug Resistance - Pathology
HIV Rides Into Cells On Membrane Rafts, NIAID Scientists Say - Pathology
High HIV Levels Shut Down Anti-HIV Immune Responses - Public Health
Peer Education Enhances Use Of Health Services Among Gay Men - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
